Previous 10 | Next 10 |
NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and pro...
– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA 50 rate and durable RECIST responses – – Data support the potential for an accelerated approval pathway in a mole...
– Bavdegalutamide demonstrated a 46% PSA 50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations – – Arvinas plans to initiate a pivotal trial by year end 2022 evalua...
ARVN is doing superb, interesting science. If successful, this company could become a game-changer. They have some upcoming catalysts. For further details see: Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma
NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences: Guggen...
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s presenters provided very encourag...
Some of the biggest gainers this year were auto stocks. Ford saw its stock shoot up nearly 125% this year. Chairman Bill Ford Jr.’s insider purchase was through a trust and eclipses his previous $8 million purchase from Aug 2019. For further details see: Insider W...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium – – ARV-471 is expected to enter two Phase 3 registrational clinical trials in 202...
Shares of ARVN (ARVN +2.2%) are higher this morning after Cowen initiated the company with an outperform rating. The firm does not have a price target. Analyst Tyler Van Buren cites potential for ARV-471 and ARV-110. The former is in phase 2 for ER+/HER- breast cancer and the latter in phase ...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...